CoronaVac

Development status

1. Emergency use/conditional marketing authorizations granted in multiple countries
2. Phase 3 clinical trials underway in multiple countries

Emergency use
authorizations granted in:

Drugs to Watch - CoronaVac

Distribution

The vaccine is easily distributed and stored.

The efficacy remains to be determined, with rates as low as 50% reported by Brazil, but the vaccine can reportedly reduce the need for hospitalization and the most severe forms of COVID-19 by 100%.